US FDA clears Iksuda Therapeutics’ IND application for IKS014
Iksuda Therapeutics, a clinical stage and UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours, announces that the US Food and Drug …